India Pharma Outlook Team | Tuesday, 06 January 2026
Wegovy pill is now available in the U.S., bringing proven GLP-1 weight-loss science into a simple once-daily tablet.
Approved on December 22, 2025, this new option expands treatment choices for more than 100 million Americans living with obesity or who are overweight with at least one related health condition. It must be used with a reduced-calorie diet and increased physical activity.
This approval marks the first time a GLP-1 weight-loss therapy can be taken without injections. For many patients, needle-free treatment removes a major barrier to starting care. Healthcare providers now have a tool that fits more lifestyles and patient preferences, which could drive broader adoption of effective medical weight management.
Also Read: Oral GLP-1 Drugs: Expanding Patient Access in Obesity and Diabetes Care
“We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them. For many of them, that wait is over as we can now offer the powerful efficacy of Wegovy in a once?daily pill that demonstrated about 17% weight loss, if all patients stayed on treatment,” said Ed Cinca, senior vice president, Marketing & Patient Solutions at Novo Nordisk.
The pill builds on the success of the Wegovy (semaglutide) injection, which has been prescribed to millions since its 2021 approval. In phase 3 trials, the oral therapy delivered weight-loss results unmatched by other oral GLP-1 obesity candidates. Patients who stayed on treatment lost an average of 16.6% of body weight, compared with 2.7% for placebo. Even when including those who didn’t complete the study, average weight loss was 13.6%, far above placebo at 2.4%.
With once-daily dosing and strong clinical results, Wegovy pill offers a new, practical option for sustained weight loss and broadens the industry’s approach to treating obesity.
.jpg)
.jpg)
